Sanofi’s Sarclisa shows significant Phase III results for multiple myeloma, delivering deeper and longer-lasting responses in ...

Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & ...

ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patientsNew analysis from the IMROZ phase 3 ...

Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight. The FDA has ...

Sanofi (SNY) says new data from three oral presentations demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly ...

Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated cell therapies for the treatment of cancer and autoimmune diseases, today ...

Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination with VRd significantly improved progression-free survival, compared to standard-of-care VRd alone If approved ...

Sarclisa has been approved in over 50 countries for certain adult patients with relapsed or refractory MM. Credit: luchschenF via Shutterstock. The European Medicines Agency’s (EMA) Committee ...

New data from three oral presentations, which demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly diagnosed multiple myeloma (NDMM) patients were featured at the 66th ...

Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination with VRd significantly improved progression-free survival, compared to standard-of-care VRd alone If approved, ...